Pfizer China and BMP Sunstone have entered into a strategic partnership to import, distribute and promote Depo-Provera (Medroxy-progesterone Acetate), a Pfizer product used to treat endometriosis, in China.
Gao Xiao Ying, director and CEO of BMP Sunstone, said: “We are very excited about our partnership with Pfizer. Depo-Provera is a great addition to our women’s health marketing and distribution portfolio in China.
“The product has already been approved by the China SFDA, and will be immediately marketable — benefiting many women who suffer from endometriosis. We are expecting to make Depo-Provera one of the cornerstone products at BMP China, and for it to drive our business growth as we introduce it to the marketplace.”
Depot medroxyprogesterone acetate (DMPA) is a progestin-only long acting reversible hormonal contraceptive birth control drug which is injected every 3 months. Depo-Provera contraceptive injection contains medroxyprogesterone acetate, a chemical similar to (but not the same as) the natural hormone progesterone that is produced by your ovaries during the second half of your menstrual cycle. Depo-Provera contraceptive injection acts by preventing your egg cells from ripening.